Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Baseline Dopamine Levels And Our Motivation To Eat Influenced By Fat Hormone
As we all know from experience, people eat not only because they are hungry, but also because the food just simply tastes too good to pass up. Now, a new study in the August 6th Cell Metabolism, a Cell Press publication, helps to explain how leptin, a hormone produced by fat tissue, influences that motivation to eat.

NMC Response To CHRE Report Re Advance Nurse Practice, UK
Following the publication of the Council for Healthcare Regulatory Excellence (CHRE) report on advanced practice, the NMC made the following statement.
News of the day
Ability To Literally Imagine Oneself In Another's Shoes May Be Tied To Empathy
New research from Vanderbilt University indicates the way our brain handles how we move through space - including being able to imagine literally stepping into someone else"s shoes - may be related to how and why we experience empathy toward others.
Endocrinology

FDA Reviewing Preliminary Safety Information On Asthma Drug Xolair

The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma. Reviewers are looking for a possible association between patients who use Xolair and an increased risk of heart attack, abnormal heart rhythm, heart failure, and stroke. The possible association has been identified based on interim results from an ongoing study of Xolair known as Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma (EXCELS). The study is being conducted by the manufacturer, San Francisco-based Genentech Inc. An FDA Early Communication is available online. The Early Communication is in keeping with the FDA"s commitment to inform the public about its ongoing safety reviews of drugs. Once its review is completed, the FDA will communicate its findings and any resulting recommendations to the public. Until the evaluation is completed, health care professionals and patients should be aware that the agency is reviewing data that may suggest a risk of adverse events. The FDA is not advising a change in prescribing or use of the drug. U.S. Food and Drug Administration


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009